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Abstract
Background: Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia
chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema,
pustular eruption, lichenoid reactions, erythroderma, and skin rash. Depigmentation of the skin and/or mucosa is
uncommon, and hyperpigmentation is rare.
Case presentation: We present the case of a 63-year-old Caucasian male with widespread hyperpigmentation of
the hard palate associated with a 9-year history of imatinib therapy to treat CML. He did not complain of any symptoms.
Clinical examination did not reveal any abnormal pigmentation of the skin or other region of the oral mucosa. He did not
smoke cigarettes or drink alcohol. His medication regimen was a proton pump inhibitor, a beta-blocker, cardioaspirin,
atorvastatin, and imatinib 400 mg/day. Histopathologically, melanin and haemosiderin deposits were evident
in the lamina propria. The lesion persisted, with no clinical change, through several follow-ups. We reviewed
the literature to explore the possible relationship between oral hyperpigmentation and long-term imatinib
mesylate treatment.
Conclusions: We diagnosed oral pigmentation associated with imatinib intake based on the medical history
and clinical features of the pigmented macules. Oral pigmentation may have a variety of causes, and differential diagnosis
requires nodal analysis. Clinicians should be aware of possible oral mucosal hyperpigmentation in patients taking imatinib
mesylate. Such pigmentation is benign and no treatment is needed, but surveillance is advisable.
Keywords: Chronic myeloid leukaemia, Oral melanosis, Drug-induced oral reactions, Oral pigmentation, Mucosal
pigmentation
Background
Pigmentation of the oral mucosa associated with over-
production of melanin is relatively common and may in-
volve any region of the oral cavity. The prevalence varies
by geographical region and ethnicity. A cross-sectional
study of 1275 Jordanian subjects found that 30.2% exhib-
ited oral pigmentation [1]. In Sweden, such lesions are
found in about 10% of the population [2]. The differential
diagnosis includes physiological and environmental
causes, as well as manifestations of systemic disease [3].
Drug-induced pigmentation constitutes 10–20% of all
cases of acquired hyperpigmentation and should be
considered during diagnosis, especially in elderly patients
on multidrug therapy [4]. The aetiology of drug-induced
pigmentation varies with the causative drug. One or more
of three potential pathways may be involved: these are de-
position of the drug per se or a metabolite thereof, stimu-
lation of melanin production, and bacterial metabolism of
the drug, alone or in combination [5]. The colour ranges
from brown (associated with the use of oral contraceptives)
to blue–black (often associated with hydroxychloroquine
treatment) [5, 6].
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Imatinib mesylate (Gleevec®; Novartis, Basel, Switzerland),
a tyrosine kinase inhibitor targeting the Bcr–Abl protein, is
a first-line treatment for Philadelphia chromosome-positive
CML [7]. The dermatological side effects include superficial
oedema and skin rash (the most frequent side effects), pus-
tular and/or lichenoid eruptions, erythroderma, graft-
versus-host-like disease, and small-vessel vasculitis [8–10].
Hypopigmentation of the skin and/or mucosa is an uncom-
mon side effect [11]. Intraoral side effects are unusual and,
in a few cases, have included lichenoid reactions [12–14]
and dental pigmentation [15–17]. Rarely, hyperpigmentation
of the hard palate has been observed, presumably related to
drug intake [3, 18–23]. Here, we describe a case of wide-
spread hyperpigmentation of the hard palate mucosa associ-
ated with long-term imatinib treatment of a CML patient.
Case presentation
In January 2016, a 63-year-old Caucasian male was
referred to us for evaluation of painless grey–blue hyper-
pigmentation of the hard palate, noted by his dentist
during a routine dental examination (Fig. 1). His medical
history included hypertension, hyperlipidaemia, and
CML diagnosed about 10 years prior. His medication
regimen was a proton pump inhibitor (20 mg/day), a
beta-blocker (50 mg/day), cardioaspirin (100 mg/day),
atorvastatin (20 mg/day), and imatinib (400 mg/day). He
had been taking imatinib for about 9 years. He had never
taken hydroxyurea, minocycline, or any anti-malarial
agent. Clinical examination revealed no abnormal pig-
mentation of the skin or other region of the oral
mucosa. He denied smoking and alcohol consumption.
We scheduled a complete blood count test and screen-
ing for Addison’s disease. No serological abnormalities
were evident. Under local anaesthesia, we performed a
3-mm incisional punch biopsy. The histopathological
report and medical history were consistent with drug-
induced palatal hyperpigmentation. We diagnosed mucosal
pigmentation associated with imatinib therapy, thus exclu-
ding other environmental, physiological, and pathological
causes (Table 1).
Histopathological findings
Histopathological examination revealed a non-inflamed
palatal mucosa with pigment-containing histiocytes in
the mucous membrane (Fig. 2). Immunohistochemically,
both haemosiderin (Perl’s Prussian blue staining) and
melanin (Fontana–Masson staining) were detected
(Figs. 3 and 4).
Outcome and follow-ups
At the 6-month follow-up, neck ultrasonography did not
reveal any swollen lymph node. We took close-up colour
photographs of the lesion to confirm the absence of any
Fig. 1 An extensive blue–grey pigmented lesion of the hard palate
mucosa evident on clinical examination
Table 1 Conditions associated with mucosal pigmentation that
should be considered during the differential diagnosis of oral
melanosis [1, 6, 25–27]
Environmental causes
Smoking-associated melanosis
Heavy metal pigmentation due to metallic deposit
Dental amalgam tattoos
Drug-induced pigmentation
Physiological causes
Physiological ethnic and/or racial pigmentation
Labial melanotic macule
Oral melanocytic nevi
Pathological causes
Post-inflammatory deposits of melanin
Peutz–Jeghers syndrome
AIDS
Hemochromatosis
Addison’s disease
Laugier–Hunziker disease
Oral melanoacanthoma
Pseudo-ochronosis
Bandler’s syndrome
McCune–Albright syndrome
Cowden syndrome
Neurofibromatosis
Riehl’s melanosis
LAMB syndrome (Carney complex)
Polyostotic fibrous dysplasia syndrome
LEOPARD syndrome
Hyperthyroidism
Nelson’s syndrome
Melanosis associated with melanoma
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morphological change. In May 2017, palatal hyperpig-
mentation was still evident, and the clinical appearance
was unchanged, but he reported no symptoms.
Discussion
Diagnostic considerations when encountering oral
melanosis should include physiological, pathological, and
environmental variables. Physiological oral melanosis is
usually localised to the gingival and buccal mucosa and
is bilateral and symmetrical, brownish in colour, and
clinically more common among dark-skinned popula-
tions [1]. Oral melanotic macules present as well-
circumscribed brown-to-black flat lesions, mainly on the
lower vermilion. The pathogenesis of physiological mel-
anotic macules remains controversial; both reactive and
genetic factors may be involved [6]. Oral nevi typically
appear as solitary brown-to-black mucosal macules, mainly
on the palate and buccal mucosa. Although the pathogen-
esis of nevi remains unknown, it has been suggested that
the lesions are benign neoplasms. No malignant transform-
ation of oral nevi has yet been reported, and no evidence
points to an increased risk of oral melanoma in affected
subjects [24]. Notably, palatal melanosis must be differenti-
ated from an oral melanoma, which may present as an
asymptomatic brown-to-grey-black macula with irregular
borders. Further, an oral melanoma grows rapidly and ex-
hibits ulcerative evolution with bleeding and pain [25].
Several systemic diseases, including Addison’s disease,
Peutz–Jeghers syndrome, McCune–Albright syndrome,
Cowden syndrome, neurofibromatosis, acquired immuno-
deficiency syndrome, haemochromatosis, and hyperthyroid-
ism, as well as uncommon conditions such as Nelson’s
syndrome, polyostotic fibrous dysplasia syndrome,
Laugier–Hunziker syndrome, and the Carney complex,
may feature oral melanotic macules [1, 26, 27]. Melanosis
associated with these conditions is due to increased levels
of melanin within the basal cell layer, attributable to incon-
tinent melanophages in the lamina propria, in the absence
of iron deposits and bleeding [3, 28]. Oral pigmentation in-
duced by smoking (smoker’s melanosis) may be associated
with the effects of components of tobacco on oral mela-
nocytes [29]. It has been hypothesised that stimulation of
melanin production may be a protective reaction of the oral
mucosa, associated with detoxification of polycyclic amines
and benzopyrenes, thus being a side effect of tobacco use
[30]. Post-inflammatory melanin deposits scattered
throughout the oral connective tissue are frequently ob-
served in patients with chronic inflammatory diseases such
as oral lichen planus, pemphigoid, and pemphigus [31].
Hyperpigmentation following inflammation may be caused
by an increase in melanogenesis triggered by cytokines and
Fig. 2 The lamina propria of the oral mucosa contained brown
pigment scattered between collagen fibres and in the cytoplasm of
macrophages (H&E ×10)
Fig. 3 The lamina propria of the oral mucosa contained blue-staining
spherical particles that included iron (Perl’s stain, ×40)
Fig. 4 The lamina propria of the oral mucosa contained brown-staining
spherical particles that included melanin (Fontana–Masson staining, ×40)
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reactive oxygen species, which induce melanocyte activity
and the proliferation of dendritic cells, and increase tyrosi-
nase activity [31, 32].
A history of occupational or environmental exposure
to heavy metals and clinical signs of metal toxicity help
to identify pigmentations of the oral mucosa. Heavy
metals such as bismuth, lead, copper, arsenic, gold, cop-
per, cobalt, chromium, silver, mercury, and magnesium
can induce the development of a bluish-black line, the
so-called Burton’s line, along the gingival margin, the
thickness of which is proportional to the extent of gin-
gival inflammation [31]. In some cases, however, the hard
palate mucosa adjacent to amalgam dental fillings de-
velops blue–grey macules, termed the “amalgam tattoo.”
Histologically, the amalgam tattoo presents as discrete
dark granules or fragments, usually surrounding collagen
bundles and blood vessels, associated with low-level infil-
trations of inflammatory cells [33]. The aetiology of
medication-associated oral pigmentation may be related
to the use of drugs that induce melanin formation. These
include clofazimine used to treat leprosy, anti-malarials
such as quinine, and immunomodulatory agents. In pa-
tients on hormonal therapy, conjugated oestrogens can
lower the serum cortisol concentration by stimulating
adrenocorticotropic hormone (ACTH) production. Not-
ably, oral hyperpigmentation induced by anti-malarials,
minocycline, and imatinib often involves the mucosa of
the hard palate [18]. Histopathologically, imatinib-induced
oral pigmentation usually presents as spherical pigmented
melanin bundles in the lamina propria, with no sign of in-
flammation or haemorrhage [3, 18–20, 23].
Of the 15 cases published in the English language lit-
erature, eight reported the histopathological features, i.e.
deposits of melanin and/or haemosiderin in the lamina
propria. Of these, four described co-existing melanin
and haemosiderin deposits. Our findings are consistent
with those of the cited reports; both Fontana–Masson
staining for melanin and Perl’s Prussian blue staining for
haemosiderin were positive (Table 2).
The pathophysiological mechanism of mucocutaneous
pigmentation induced by imatinib remains unclear. Ima-
tinib targets the ATP-binding site of the Bcr–Abl tyro-
sine kinase and also inhibits the actions of other tyrosine
kinases, including platelet-derived growth factor
receptor-b, C-kit, and C-ABL [17]. C-kit is a transmem-
brane growth factor expressed in basal skin cells, mela-
nocytes, epithelial cells of the breast, and mast cells,
stimulation of which leads to activation (followed by the
Table 2 Summary of previous case reports on oral mucosal pigmentation associated with imatinib therapy
Author(s), year Duration of
treatment
with imatinib
Dosage
(mg/dose)
Age and sex
of patient
Site(s)
affected
Histological
findings
Condition
treated
Singh and Bakhshi
2007 [15]
4 years 300 13 F Gingivae, teeth Clinical diagnosis only CML
Lewis, 2009 [18] Unknown 800 70 M Palate Melanin and haemosiderin deposits in
lamina propria
CML
Mcpherson et al.
2009 [38]
6 years Unknown 59 F Gingivae, toes,
fingernails
Clinical diagnosis only CML
Wong et al. 2011
[19]
3 months Unknown 43 F Palate Melanin deposits in lamina propria CML
Mattsson et al. 2011
[20]
5 years
5 years
5 years
400
400
400
66 F
66 F
64 F
Palate
Palate
Palate
Melanin deposits in lamina propria
Clinical diagnosis only
Metastatic gastrointestinal
stromal tumour
CML
CML
Li et al. 2012 [3] 4 years
10 years
5 years
400
400
400
64 M
53 M
29 F
Palate
Palate
Palate
Melanin and haemosiderin deposits
in lamina proria
CML
CML
Pelvic fibromatosis
Resende et al. 2012
[21]
5 years 600 38 M Palate, nose,
earlobes
Clinical diagnosis only Post-haematopoietic stem
Cells transplant
Roeker and
Wolanskyj 2014 [22]
6 years Unknown 65 F Palate Clinical diagnosis only CML
Song and Kang
2014 [23]
Unknown Unknown 58 M Palate, nose Clinical diagnosis only CML
Lyne et al. 2015
[24]
13 years 400–600 58 F Palate Haemosiderin deposits in lamina
propria
CML
Romeo et al. 2015
[39]
11 years 400 72 F Palate Brown spherical bodies located within
the lamina propria
CML
CML chronic myeloid leukaemia
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rapid degradation) of microphthalmia transcription
factor (MITF); in turn, this transactivates the promoter
of the tyrosinase pigmentation gene of melanocytes [9].
It has been suggested that imatinib inhibits ligand bind-
ing to specific receptors on the surfaces of human
melanocytes, reducing cellular activity and thus
commonly triggering hypopigmentation [10]. However,
imatinib may rarely cause hyperpigmentation of the skin
and/or mucosae; a metabolite of the drug may chelate
iron and melanin, as do minocycline and anti-malarial
drugs [3]. Currently, it is not known why the mucosa of
the hard palate is the tissue invariably affected by hyper-
pigmentation. However, the palate contains a large num-
ber of mucosal melanocytes [34] in which imatinib
metabolites accumulate. Also, C-kit signalling may play
a role in oral hyperpigmentation, and indeed, C-kit is
widely expressed in mesenchymal cells of the human
oral cavity, including dental pulp cells and gingival fi-
broblasts [35]. In addition, the cases of oral hyperpig-
mentation reported to date do not appear to be drug
dose-dependent (Table 2). Only a few oral mucosal hyper-
pigmentation cases caused by administration of imatinib
mesylate to treat haematological malignancies have been
reported. Hence, it remains speculative to suggest that
imatinib mesylate may directly influence melanocyte C-kit
signalling in the oral mucosa, activating melanogenesis. It
is possible that genetic and/or other factors are also in-
volved in the development of oral melanotic maculae.
Finally, the time of onset of CML may be relevant; some-
times, patients are treated initially with hydroxyurea,
which may also cause mucocutaneous hyperpigmentation
and melanonychia [36–39].
Conclusions
The diagnosis of imatinib-associated oral pigmentation
requires a thorough history-taking and clinical examin-
ation of the melanotic maculae. Medical and dental
practitioners should be aware of possible oral mucosal
hyperpigmentation in patients taking imatinib mesylate.
The hyperpigmented lesions are benign; no treatment is
required. However, annual follow-up is advisable to
monitor changes in morphology or colour over time.
Abbreviation
ACTH: Adrenocorticotropic hormone; CML: Chronic myeloid leukaemia;
MITF: Microphthalmia transcription factor
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